News
The ASAM Weekly for November 17, 2026
GLP-1 RAs (glucagon-like peptide-1 receptor agonists) haven’t been brought up in a minute. A national survey found that half of people using a GLP-1 RA reported a reduction in alcohol consumption, especially those with more unhealthy drinking patterns. A separate Science report reviews the mechanism GLP-1 RAs may have on addiction pathways. We have yet to fully understand the implications of GLP-1 RAs in our patients, but many of us are certainly seeing the impacts.
Harm reduction is a proven strategy in addiction treatment. While overdose prevention centers (OPCs) continue to be debated, OPC utilizers report positive outcomes in NYC. City programs, such as mobile units for addiction and HIV prevention in people who inject drugs, can achieve objective outcomes like reduced mortality. Interestingly, KFF reports that much of the opioid settlement funds go to housing, more than to overdose reversal drugs and approaching the amount put toward prevention, even though most unhoused people don’t use illicit substances.
While it is hard to make sense of how opioid settlement funds are being used (and the KFF article above is a great resource), something that is well established in MOUD care is the effectiveness of buprenorphine-naloxone. When a treatment or screening is foundational, measurement-based care (MBC) can be instrumental to increase adoption. In a recent JSAT article, researchers describe development of an EHR-integrated MBC tool to improve MOUD outcomes. Still, more study is needed to perfect such an approach without it feeling like surveillance or punitive.
While I opened and closed with uncertain topics, two more emerging trends deserve our attention: the rise of gambling among college students and how prediction markets are impacting tribal revenues. Adding another layer of complexity, a recent Atlantic piece examines how AI is infiltrating academic publishing. We’ll continue bringing you regular and guest editorials in the coming weeks to highlight the latest developments in addiction medicine. Until then, happy reading, and keep a sharp eye on the evolving evidence.
Smita Das, MD, PhD, MPH
Editor in Chief
with Co-Editors: Brandon Aden, MD, MPH, FASAM; John A. Fromson, MD; Sarah Messmer, MD, FASAM; Jack Woodside, MD; and Contributing Editor: Jessica Gregg, MD, PhD, FASAM
Journal of Addiction Medicine Editorial Fellowship Program
Deadline Extended
The Journal of Addiction Medicine (JAM) seeks 3 Editorial Fellows to serve a 2-year term. Fellows will commit to 3-4 hours per week and participate in weekly 30-minute conference calls with the editorial team.
Deadline to apply*: November 17, 2026
*To Apply:
ASAM Members: Log into the portal, click Forms, Online Forms, and select Editorial Fellows Application.
Non-members: Set up an account, then follow the instructions above.
Using a nationally representative survey of US adults, this study estimated the population prevalence of patient-reported reductions in alcohol use following glucagon-like peptide-1 receptor agonist (GLP-1 RA) initiation and assessed public awareness of the potential impact of GLP-1 RAs on alcohol use. Researchers found that nearly half of individuals who used a GLP-1 RA reported they reduced their alcohol consumption; individuals with potentially unhealthy drinking were more likely to report reductions. Although large clinical trials are needed to draw conclusions about the relationship between GLP-1 RAs and alcohol use, it is notable that such a large fraction of GLP-1 users in this survey reported reductions.
This perspective piece discusses the unique role of GLP-1 RAs, used to treat obesity and type 2 diabetes, as potential treatments for addictions. Highly palatable, energy-dense foods elicit a strong dopamine-related reward response, resulting in compulsive use similar to drug use. GLP-1 RAs attenuate the dopamine response and the associated compulsive use. Current treatments target specific substances, like alcohol, opioids, or nicotine, while GLP-1 RAs may treat addiction in general. GLP-1 RAs also affect other areas of the brain associated with stress, emotions, and prefrontal executive control, which also play roles in addiction. In addition to effects throughout the GI tract, GLP-1 RAs also influence the immune system and inflammation. They may offer comprehensive addiction treatment involving brain, body, and behavior.
This open-label randomized clinical trial from May 2021 to September 2024 compared two different care delivery models for people currently injecting drugs: integrated peer navigation, PrEP, MOUD, and support services delivered via mobile unit versus peer navigation to community-based PrEP, MOUD, and support services. The study was conducted in Houston, Los Angeles, New York City, Philadelphia, and Washington, DC. A total of 409 individuals were randomized to either the mobile unit or control intervention for 26 weeks, with additional follow-up at 52 weeks. After 26 weeks there were no statistically significant differences between study arms for verified PrEP use or MOUD engagement. However, there was a statistically significant reduction in all-cause mortality in the mobile unit arm, with a 71% lower risk of death as compared to the control arm at 52 weeks.
Researchers conducted 40 semi-structured interviews with participants utilizing overdose prevention center (OPC) services in New York City. Participants were 18 or older, enrolled in syringe service program services at either of two OPC sites, and had utilized OPC services at least once in the last 30 days. Three themes were identified: (1) OPCs are a safe haven that mitigate drug-related harms including overdose and violence, (2) compassionate non-judgmental care is a key component of OPC services, and (3) participants adopt safer drug use practices after receiving harm reduction education and support services at the OPC.
Measurement-based care (MBC) uses patient-reported outcome measures (PROMs) to guide treatment, but for those with opioid use disorder it could feel like surveillance and punitive. Researchers describe the development of a buprenorphine MBC using an iterative co-design strategy. Some of the key components included a patient-initiated outcome option and the need for brief assessments with feedback to patients that thanked them for honesty. Researchers also identified cravings as an early signal of recurrent opioid use and added a craving scale. In addition, identifying withdrawal and side effects helped guide dose adjustments as patients reported uncertainty about requesting dose changes. By aligning the MBC with patient and clinician experiences the intervention could provide for more collaborative care, but additional research is needed to evaluate outcomes for the developed MBC.
Behavioral Addictions Volume of The ASAM Criteria, 4th Edition
Now through November 20, the American Society of Addiction Medicine (ASAM) is seeking public comment on a draft Framework for the Behavioral Addictions Volume of the 4th Edition of The ASAM Criteria®.
For more information and instructions to review, please click here.
This study used transcranial magnetic stimulation (TMS) precisely targeted to the anterior cingulate cortex (ACC) in rats trained to self-administer oxycodone to reduce drug-seeking relapse behavior during a period of abstinence. The ACC assesses rewards and exerts cognitive control of actions through connectivity with regions including the nucleus accumbens (NAc) and the motor cortex (Mc). During a 15-day period of abstinence the oxycodone-trained rats showed a progressive increase in oxycodone seeking over the 15-days period, and functional MRI showed a decrease in connectivity from ACC to the NAc and the Mc. Seven days of TMS to the ACC during the abstinence period blocked the increase in oxycodone seeking and the decrease in ACC connectivity. The authors concluded that in opioid addiction, TMS to the ACC has promise for reducing drug seeking and relapse during periods of abstinence.
While standard methadone titration minimizes risk of toxicity, rapid titration could potentially increase treatment retention and decrease ongoing non-prescribed opioid use earlier. Researchers conducted a systematic review to assess evidence for rapid titration protocols, including 29 studies covering both inpatient and outpatient protocols. Overall, there was significant variability in titration strategies with day-7 doses ranging from 53 mg to 200 mg. Reported morbidity and mortality included 63 deaths, though not specifically attributed to methadone and none occurring after the advent of fentanyl in the drug supply. The authors note the overall data were of low quality and, while rapid titration may increase retention, rigorous studies with long-term follow-up are needed.
This study of 105 patients with moderate-to-severe cocaine use disorder and 80 healthy volunteers examined how explicit rewards, losses, and probabilities influence decision-making, with a subset also undergoing brain imaging. Patients used probability information similarly to healthy volunteers but incorporated outcome information, particularly losses, less. Although the groups did not differ in orbitofrontal striatal white matter tracts, individual variation in these pathways predicted how strongly rewards and losses influenced decisions, regardless of diagnosis. These findings suggest that people with cocaine use disorder may need additional support using potential consequences, especially negative ones, to make adaptive choices during recovery.
- As overdose deaths fall, a changing drug supply is making Philadelphia’s opioid crisis harder to escape 🔓WHYY
- Could it have saved him? Few get long-term help under new conservatorship law 🔓CalMatters
- Tribes, frustrated by prediction markets, hope new Congress will step in 🔓Milwaukee Journal Sentinel
- House education committee tackles gambling among college students 🔓Inside Higher Ed
- Opioid settlement cash and homelessness: It’s not always clear how addiction fits in 🔓KFF Health News
- Alcohol consumption is growing in key markets worldwide, report says 🔓Forbes
- The currency of the journal article is collapsingThe Atlantic